Medical Devices · Acton, Massachusetts, United States
$138.13
-2.03% (-$2.86)2026-10-13
Smart-Money SignalNeutral · 52/100— Insiders are net buyers over 90 days ($162K, 1 buy vs 0 sales)
Revenue$801.7M
Net Income$95.0M
EPS$2.67
Gross Margin70.2%
Market Cap$9.6B
Price Performance
Historical data including institutional events
Company Profile
A
Ashley McEvoy
CEO & Executive Director
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy.
The company sells its products to end-users through the pharmacy channel; and independent distributors.
Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.